30 closest matches · ranked by relevance
Skull Base Neoplasms · Skull Neoplasms · Bone Neoplasm
Primary: ICG Fluorescence Ratio — 0.92; 0.82 Ratio
Metastatic Brain Tumor · Primary Brain Tumor · Epileptic/Seizure Foci
Primary: Safety (Reportable Adverse Events) — 1; 7; 2; 30 Participants
Thoracic Surgery · Cardiopulmonary Bypass
Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
Intracranial Aneurysm · Brain Edema · Scoliosis
Primary: Number of ICU Stays Greater Than 1.5 Days — 13; 20 Number of ICU Stays greater that 1.5 Day
Metastatic Brain Tumors · Progression · Radiation Necrosis
Primary: Percentage of Patients With Progression-Free Survival (PFS) — 74; 74 percentage of patients
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Cerebral Aneurysm Unruptured · Cerebral Aneurysm Ruptured
Primary: Aneurysm Clip Time
Cerebrospinal Fluid Leak
Primary: Primary Effectiveness Endpoint Success Number of Successes (Subjects That Had no Inter-operative CSF Leak Following Valsalva Maneuver and no CSF Leak or…
Intracranial Hemorrhage
Primary: Number of Participants With Modified Rankin Score (mRS) ≤ 3 or mRS > 3 — 17; 20 Participants
Glioma
Primary: Extent of Resection — 24; 25 participants
Hemostasis · Meningioma Surgery
Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…
Surgical Wound Infections
Primary: Incidence of Infection That Requires Removal of the Neurosurgical Device — 97; 98 Participants
Intracranial Surgery
Primary: Hourly Pain Scores — 2.5; 3.6; 3.7; 5.2 units on a scale
Hypertension · Brain Tumor · Epilepsy
Primary: The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine…
Cerebral Hemorrhage · Brain Hemorrhage · Cerebral Parenchymal Hemorrhage
Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Intracerebral Hemorrhage
Primary: Safety Outcome Number 1: Rate of Mortality — 9.5; 14.8; 7.1 percentage of participants — p=0.324
Intracerebral Hemorrhage
Primary: Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted) — 110; 100; 139; 140 Participants — p=0.73
Brain Metastases
Primary: The Number of Subjects Undergoing Resection Following SRS. — 11 Participants
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
Head Trauma · Crushing Skull Injury · Head Injury
Primary: Infrascanner 2500™ Diagnostic Performance — 79; 65; 27; 9 Participants
Infection · Surgery · Nervous System Diseases
Primary: Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office…
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
Parkinson's Disease
Primary: Change in Motor OFF Ldopa UPDRS — 14.8 motor UPDRS
Parkinson's Disease
Primary: "Off" and "On" Medication Unified Parkinson's Disease Rating III Score (UPDRS) — 48.4; 28.9; 23.52; 22.56 units on a scale — p=<0.001
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants